In glioma, an upregulated expression of inhibitory checkpoint proteins, PD-1 (and its ligand PD-L1) and CTLA-4, have been associated with immune evasion, increased tumor grade and poor patient prognosis [167]. Here, CTLA4 is linked to neoplasm.